Fortress Biotech, Inc. (FBIO) Gross margin 2016–2025
Fortress Biotech, Inc. (FBIO) gross margin by fiscal year — reported gross profit divided by reported revenue.
66.9%FY2025 · since FY2016: 95.2% → 66.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 66.9% | +3.1 pp |
| FY2024 | 63.8% | -9.1 pp |
| FY2023 | 72.9% | +13.5 pp |
| FY2022 | 59.4% | +6.0 pp |
| FY2021 | 53.4% | -14.6 pp |
| FY2020 | 68.0% | -3.3 pp |
| FY2019 | 71.2% | -6.0 pp |
| FY2018 | 77.2% | -1.6 pp |
| FY2017 | 78.8% | -16.4 pp |
| FY2016 | 95.2% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIO financial trends
FBIO RevenueFBIO Net incomeFBIO Net marginFBIO Gross profitFBIO Operating incomeFBIO Operating marginFBIO Operating cash flowFBIO Free cash flowFBIO Capital expendituresFBIO Return on equityFBIO Stock buybacksFBIO Dividends paidFBIO Total assetsFBIO Total liabilitiesFBIO Shareholders’ equityFBIO overview →